The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

Follicular lymphoma is a typically slow-progressing B-cell lymphoproliferative disease that originates from transformed follicular center B cells. It is commonly marked by widespread lymph node ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous ...

Follicular lymphoma is a form of non-Hodgkin lymphoma. It’s usually slow-growing and responds well to treatment but is difficult to cure. Since it is a slow-moving cancer, doctors and patients ...

Tafasitamab was previously approved with lenalidomide for r/r diffuse large B-cell lymphoma not otherwise specified and ineligible for autologous stem cell transplant. The inMIND trial randomized ...

Company News Published 06/18/2025, 03:45 PM 0 FDA approves Monjuvi combination therapy for follicular lymphoma INCY -3.45% ...

In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise ...

Follicular lymphoma represents up to 30% of non-Hodgkin lymphoma. It has historically been challenging to treat given its tendency for frequent relapse and potential to turn into large B-cell ...

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma - Monjuvi® (tafasitamab ...